Study of retifanlimab, bevacizumab, and radiation for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with glioblastoma (a type of brain tumor) that has come back after previous treatment.
- You are able to have radiation therapy.
- Your daily steroid dose (dexamethasone) is 4 mg or less at the start of the study.
- You are in fairly good health, able to care for yourself (Karnofsky score of 60% or higher).
- Your blood counts and organ function tests are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether using special MRI information to plan proton radiation, plus a drug called Avastin (bevacizumab), can help control recurrent glioblastoma (a fast-growing brain tumor) and improve outcomes. It mainly aims to treat tumor that has come back after prior standard radiation, using careful timing and imaging to target it safely.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
This trial tests combining two drugs, actimab-A and cemiplimab, for people whose glioblastoma has come back after prior treatment. The goal is to see if this combination can improve outcomes.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.